Core Insights - The article highlights the significant achievements and strategic direction of Jiuzhoutong Group, emphasizing its dual listing and extensive logistics network coverage across China [3][4]. Group 1: Company Achievements - Jiuzhoutong Group participated in a meeting for private enterprises, reflecting the support from the government for business development [3]. - The company has launched a dual listing, becoming the only dual-listed company in the Chinese pharmaceutical industry, with its public REITs debut on February 27 [3]. - Jiuzhoutong celebrated its 40th anniversary with impressive financial results, reporting over 150 billion yuan in revenue for two consecutive years, and operates 687 subsidiaries with a logistics network covering over 96% of administrative regions in China [3]. Group 2: Strategic Initiatives - The company is advancing its "Three New and Two Transformations" strategy, focusing on new products, new retail, new healthcare, digitalization, and real estate securitization [3]. - Jiuzhoutong has been recognized as the 55th in the latest list of China's top 500 private enterprises and ranks 4th in the pharmaceutical commercial industry, leading as the top private pharmaceutical distributor [4].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600998 证券简称：九州通 公告编号：临2025-098 九州通医药集团股份有限公司 关于全资子公司参与重整投资的奥园美谷科技股份有限公司 重整计划执行完毕的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 2025年4月23日，九州通全资子公司九州产投公司与奥园美谷及其预重整期间临时管理人签订《重整投 资协议》，拟出资673,200,000.00元取得重整后奥园美谷360,000,000股转增股票。公司于2025年4月22日 召开第六届董事会第十三次会议及第六届监事会第十一次会议，审议通过《关于全资子公司签署〈奥园 美谷科技股份有限公司重整投资协议〉的议案》。根据《上海证券交易所股票上市规则》《公司章程》 等相关规定，本次投资事项在公司董事会审批权限内，无需提交公司股东会审议。具体详见公司于2025 年4月24日在上海证券交易所网站（www.sse.com.cn）披露的《九州通关于全资子公司签署〈奥园美谷 科技股份有限公司重整投资协议〉的公告》（公告编号：临 ...

2025 年 11 月 14 日，奥园美谷收到湖北省襄阳市中级人民法院（以下简 称"襄阳中院"）送达的《民事裁定书》及《决定书》，襄阳中院裁定受理奥园美 谷重整申请，并指定奥园美谷清算组担任奥园美谷管理人。具体详见公司于 2025 年 11 月 17 日在上海证券交易所网站（www.sse.com.cn）披露的《九州通关于全 资子公司参与重整投资的奥园美谷科技股份有限公司获法院裁定受理重整并指 定管理人的进展公告》（公告编号：临 2025-082）。 2025 年 12 月 16 日，奥园美谷收到襄阳中院送达的《民事裁定书》（（2025） 鄂 06 破 17 号），襄阳中院裁定批准《奥园美谷科技股份有限公司重整计划》（以 下简称"《重整计划》"），并终止奥园美谷重整程序。具体详见公司于 2025 年 12 证券代码：600998 证券简称：九州通 公告编号：临 2025-098 九州通医药集团股份有限公司 关于全资子公司参与重整投资的奥园美谷科技股份有限公司 重整计划执行完毕的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任 ...

Core Viewpoint - The announcement indicates that a subsidiary of the company has received regulatory approval for a new drug, which may enhance its product portfolio and market position in the pharmaceutical industry [2] Group 1 - On December 26, the company announced that its subsidiary, Beijing Jingfeng Pharmaceutical Group Co., Ltd., received a drug registration certificate for Isopropamide Iodide Injection from the National Medical Products Administration [2] - The approval is significant as it allows the company to market and distribute this medication, potentially increasing its revenue streams [2] - The drug registration certificate was issued on December 25, 2025, marking a key milestone in the company's product development timeline [2]

Group 1 - Zhuolang Intelligent's subsidiary plans to increase capital by 900 million yuan to its wholly-owned subsidiary in Xinjiang [1] - Zhenhua Heavy Industry signed a contract worth 1.149 billion yuan with Guangzhou Salvage Bureau for a deep-water crane ship construction project [2] - Ugreen Technology intends to issue H-shares and apply for listing on the Hong Kong Stock Exchange to enhance its global strategy [3] Group 2 - Guangsheng Nonferrous Metals will change its stock name to Zhongxi Rare Metals starting December 31, 2025 [4] - China Electric Research proposed a cash dividend of 2.5 yuan per 10 shares for the first three quarters of 2025 [5] - Chaoyan Co. is establishing a fund with professional investment institutions, aiming to raise 1 billion yuan [6] Group 3 - Silk Road Vision's subsidiary plans to sell 8.5% of Ruijun Technology for 52.7 million yuan [7] - Longgao Co.'s actual controller is transferring 4.37% of the investment development group's equity for 398 million yuan [8] - Weiteou signed a strategic cooperation agreement with Huaruixin Energy to develop new materials and applications [9][10] Group 4 - Annuoqi decided to terminate the investment in a 50,000-ton dye intermediate project due to market changes, with a total investment of 421 million yuan [12] - Akoli's subsidiary has entered trial production for a project with an annual capacity of 20,000 tons of polyether amine [13] - Ningbo Construction's subsidiary signed a construction contract worth 451 million yuan for a comprehensive utility tunnel project [14] Group 5 - Zhejiang Rongtai and Weichuang Electric plan to establish a joint venture in Thailand for R&D and production of mechatronic components [15] - Jiuzhoutong's subsidiary received a drug registration certificate for isopropazine injection [16] - Huaqin Technology's subsidiary signed a daily operation contract worth 392 million yuan [17] Group 6 - ST Meichen completed the sale of 100% equity in Hainan Meichen Ecological Development Co., Ltd. [18] - Pulite's LCP film products have begun mass production for a leading customer in the consumer electronics industry [19][20] - Nanjing Public Utility's major shareholder transferred 7.61% of the company's shares for 300 million yuan [21] Group 7 - Solar Energy terminated the investment in a 150 MW distributed photovoltaic project due to increased investment risks [22] - Yuntian Lifa won a 122 million yuan project for AI development in Longgang [23] - Changchun High-tech's subsidiary received acceptance for a clinical trial application for GenSci141 ointment [24] Group 8 - Changfei Optical Fiber's major shareholder completed a share reduction plan, selling 1.1 million shares for approximately 104.5 million yuan [25] - Sandam Membrane plans to apply for a comprehensive credit limit of up to 100 million yuan for 2026 [26] - Aisecurity received a government subsidy of 3.4611 million yuan [27] Group 9 - Stone Technology's H-share issuance has received approval from the China Securities Regulatory Commission [28] - Hongxing Development's subsidiary plans to suspend production to comply with national hazardous chemical relocation policies [29] - Guodian Nanzi's vice president and chief engineer resigned [30] Group 10 - Jianghe Group's subsidiary won a bid for a city renovation project in Haikou worth approximately 112 million yuan [31] - Gaotie Electric's subsidiary won a bid for a railway project worth 59.0317 million yuan [32] - Huicheng Co. plans to introduce a new partner to its major shareholder [33] Group 11 - Pumen Technology's folic acid testing kit received a medical device registration certificate [34] - Hai Xin Co.'s vitamin B6 injection passed the consistency evaluation for generic drugs [35] - Taiji Group's shareholder plans to merge with its subsidiary [36] Group 12 - Shengyi Electronics adjusted the maximum repurchase price to no more than 144.36 yuan per share [37]

证券代码：600998 证券简称：九州通 公告编号：临 2025-097 九州通医药集团股份有限公司 关于盐酸异丙嗪注射液获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2025 年 12 月 25 日，九州通医药集团股份有限公司（以下简称"公司"或 "九州通"）子公司北京京丰制药集团有限公司（以下简称"京丰制药"）的下 属公司汇禹远和（海南）药业有限公司（以下简称"汇禹远和"）收到国家药品 监督管理局核准签发的盐酸异丙嗪注射液《药品注册证书》。现将相关情况公告 如下： 一、药品注册证书主要信息 药品名称：盐酸异丙嗪注射液 剂型：注射剂 申请事项：药品注册（境内生产） 规格：2ml：50mg；1ml：25mg 注册分类：化学药品 3 类 证书编号：2025S03881；2025S03882 药品批准文号：国药准字 H20256348；国药准字 H20256349 药品批准文号有效期：至 2030 年 12 月 21 日 上市许可持有人：汇禹远和（海南）药业有限公司 药品生产企业：浙江赛默制药有限公司 审 ...

Core Viewpoint - The company announced that its subsidiary, Beijing Jingfeng Pharmaceutical Group Co., Ltd., received approval from the National Medical Products Administration for the registration of Isopropamide Iodide Injection, indicating a significant advancement in its product portfolio [1] Group 1 - The approved drug, Isopropamide Iodide Injection, is an antihistamine used for treating skin and mucosal allergies, motion sickness, and as an adjunct treatment before and after anesthesia, as well as for preventing radiation sickness or drug-induced nausea and vomiting [1] - As of the date of the announcement, the company has invested approximately RMB 4.67 million (unaudited) in the research and development of this drug [1]

Group 1 - The core point of the article is that Jiuzhoutong (600998.SH) announced that its subsidiary, Beijing Jingfeng Pharmaceutical Group Co., Ltd., received approval from the National Medical Products Administration for the drug registration certificate of Isopropamide Iodide Injection [1] - Isopropamide Iodide Injection is an antihistamine drug used for treating skin and mucosal allergies, motion sickness, and as an adjunct treatment before and after anesthesia and surgery, as well as for preventing and treating radiation sickness or drug-induced nausea and vomiting [1]

Core Viewpoint - The approval of the drug "Isopropamide Iodide Injection" by the National Medical Products Administration is a significant milestone for the company, enhancing its product pipeline and market competitiveness [2] Group 1: Company Developments - The subsidiary of the company, Jingfeng Pharmaceutical, received a drug registration certificate for Isopropamide Iodide Injection, an antihistamine used for skin and mucosal allergies and motion sickness [2] - The company has invested approximately 4.67 million yuan in the research and development of this drug [2] Group 2: Market Implications - The approval of this drug is expected to help the company expand its market share and enrich its injectable product line [2] - There are uncertainties regarding production and sales scale due to factors such as national policies and market environment [2]

Core Viewpoint - Kyushu Tong (600998.SH) announced that its subsidiary, Beijing Jingfeng Pharmaceutical Group Co., Ltd., received approval from the National Medical Products Administration for the drug registration certificate of Isopropamide Iodide Injection, indicating a significant development in its product portfolio [1] Group 1 - The approved drug, Isopropamide Iodide Injection, is an antihistamine used for treating skin and mucosal allergies, motion sickness, and as an adjunct treatment before and after anesthesia and surgery [1] - The drug also serves to prevent and treat radiation sickness or drug-induced nausea and vomiting, highlighting its therapeutic versatility [1]